Evidence map›Paper›PMID 32223390›Full record

SynthesisJournal of the American Heart Association2020

Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis.

Mengdie Hu, Xiaoling Cai, Wenjia Yang, Simin Zhang, Lin Nie, Linong Ji

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of the American Heart Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 6 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 6 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025 · on this map
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. SGLT2 inhibitors and lower limb complications: an updated meta-analysis.Cardiovascular diabetology · 2021 · on this map
    Pooled it
  6. Pooled it
  7. Long-term effects of ipragliflozin on blood pressure in patients with type 2 diabetes: insights from the randomized PROTECT trial.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Observational
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mengdie HuDepartment of Endocrinology and Metabolism Peking University People's Hospital Beijing China.
Xiaoling CaiDepartment of Endocrinology and Metabolism Peking University People's Hospital Beijing China.
Wenjia YangDepartment of Endocrinology and Metabolism Peking University People's Hospital Beijing China.
Simin ZhangDepartment of Endocrinology and Metabolism Peking University People's Hospital Beijing China.
Lin NieDepartment of Endocrinology and Metabolism Beijing Airport Hospital Beijing China.
Linong JiDepartment of Endocrinology and Metabolism Peking University People's Hospital Beijing China.
Peking University · CNAirport Shunyi District Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) have shown their beneficial effects on cardiovascular outcomes and multiple cardiovascular risk factors, including hypertension. However, the mechanism of blood pressure (BP)-lowering effects of these agents has not been elucidated. This study aims to evaluate the effect of hemoglobin A1c reduction or body weight reduction with GLP-1RA treatment and SGLT2i treatment on BP changes in patients with type 2 diabetes mellitus. Methods and Results Studies were identified by a search of MEDLINE, EMBASE, and the Cochrane Central Register until June 2019. Meta-regression analysis was performed to evaluate the association between hemoglobin A1c reduction or body weight reduction and changes of BP. A total of 184 trials were included. Both GLP-1RA and SGLT2i led to significant reductions in systolic BP (weighted mean difference, -2.856 and -4.331 mm Hg, respectively;

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsAgedBiomarkersBlood GlucoseBlood PressureDiabetes Mellitus, Type 2FemaleGlucagon-Like Peptide-1 ReceptorGlycated HemoglobinHumansIncretinsMaleMiddle AgedSodium-Glucose Transporter 2 InhibitorsTreatment OutcomeWeight LossBiomarkersBlood GlucoseGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsGlycated Hemoglobinhemoglobin A1c protein, humanIncretinsSodium-Glucose Transporter 2 Inhibitorsblood pressureglucagon‐like peptide‐1 receptor agonistsmeta‐analysissodium‐glucose cotransporter‐2 inhibitorstype 2 diabetes mellitus

Identifiers

PMID32223390
PMCPMC7428598
OpenAlexW3013579324

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.